Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. develops plant-based compounds through its proprietary Botanical Synthesis technology platform, which is designed to grow plant compounds without cultivating the underlying plant. Company news centers on two business verticals: a direct-to-consumer products business built around proprietary nutraceutical health and wellness products, including VINIA, and a CDMO business serving customers seeking novel plant-based compounds.
Recurring updates include financial results, product commercialization, direct-to-consumer growth, CDMO development programs, and applications of the platform in areas such as nutraceuticals and fragrance molecules. BioHarvest also reports governance and leadership changes, equity-based compensation actions, financing activity, and conference participation tied to its public-company profile.
BioHarvest Sciences (NASDAQ: BHST) completed Stage 1 of a multi-stage CDMO development agreement with SaffronTech, establishing a stable saffron cell bank for nutraceutical and culinary uses. The agreement is valued at $1.125 million, with BioHarvest also holding a 25% stake in Saffron Composition and future royalty rights.
BioHarvest Sciences (NASDAQ: BHST) signed a $1.2 million Stage 2 CDMO contract to develop a rare fragrance raw material using its Botanical Synthesis platform. The deal follows Stage 1 completion in March 2026, when a stable cell bank containing rare molecules was created.
Stage 2, lasting about six to nine months, aims to produce enough material for commercial trials. BioHarvest keeps 20% ownership of successful compositions and is positioned to earn manufacturing revenue and future royalties, targeting production in the second half of 2027.
BioHarvest Sciences (NASDAQ: BHST) will report first quarter 2026 financial results before market open on Thursday, May 14, 2026.
The company will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss results and business operations; a replay will be posted in Investor Relations/Events & Presentations.
BioHarvest (NASDAQ: BHST) announced a strategic leadership transition effective April 29, 2026: Co-Founder Dr. Zaki Rakib assumes the role of Chief Executive Officer, consolidating R&D, Manufacturing, and Operations under the CDMO; Ilan Sobel moves from CEO to the Board to focus on D2C.
The change supports the company's stated "two-lens" strategy across the D2C VINIA business and its CDMO platform; fiscal year 2025 revenue was reported at approximately $35 million.
BioHarvest Sciences (NASDAQ: BHST) reported FY2025 revenue of $34.5M, up 37% year-over-year, and Q4 revenue of $9.1M, up 25% YoY. Gross margin was ~59% for FY2025. Cash and equivalents totaled $23.0M as of Dec 31, 2025. The company completed an oversubscribed institutional financing of $19.9M in November 2025 and raised an additional $10.9M from warrant exercises and debt conversions. 2026 consolidated revenue guidance is $42–48M with adjusted EBITDA loss guidance of ($3–4M). 2026 CDMO revenue guidance is $4–6M (total CDMO incl. intercompany $12–14M) with expected CDMO adjusted EBITDA loss of ($4–5M).
BioHarvest Sciences (NASDAQ: BHST) announced that its CDMO division completed Stage 1 of a multi-stage program, creating the first-ever stable cell culture for a rare, endangered fragrance plant using its Botanical Synthesis platform.
BioHarvest retains 20% ownership of developed compositions; biomass for pre-commercial testing is expected in 6–9 months, with industrial-scale manufacturing anticipated in 12–18 months. Company cites a $23B premium fragrance segment within a $58.9B industry opportunity.
BioHarvest Sciences (NASDAQ: BHST) announced that VINIA is the No.1 Resveratrol Polyphenol nutraceutical brand in the United States as of March 26, 2026.
Key metrics: U.S. revenue > $30 million in 2025, $85 million global cumulative revenue to date, ~85,000 active users, and VINIA.com accounts for ~80% of U.S. VINIA revenue. The company cites Botanical Synthesis technology that preserves plant-cell structure and magnifies piceid resveratrol up to 100x. The #1 ranking is based on NIQ 2025 market projections and Amazon sales estimates.
BioHarvest Sciences (NASDAQ: BHST) will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The company will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and business updates.
Investors can register for the live webcast and replay will be posted in the Investor Relations/Events & Presentations section of the company's website.
BioHarvest (NASDAQ: BHST) announced a board transition on March 5, 2026: Mr. David Tsur will step down after more than four years, and Prof. Hezi Levy is appointed to the Board effective immediately.
Prof. Levy brings decades of Israeli healthcare leadership, including Director General of the Ministry of Health and Head of IDF Medical Corps.
BioHarvest Sciences (NASDAQ: BHST) will participate in the 38th Annual Roth Conference on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. CEO Ilan Sobel is scheduled for one-on-one meetings with institutional investors.
According to the company, BioHarvest completed a successful Q4 2025 financing, is fully funded for near-term CapEx, and has over 85,000 direct customers as it focuses on growth in CDMO and consumer product businesses.